Eagle Pharmaceuticals Inc. (EGRX)

55.92
NASDAQ : Health Technology
Prev Close 58.22
Day Low/High 55.63 / 58.69
52 Wk Low/High 36.03 / 82.33
Avg Volume 138.40K
Exchange NASDAQ
Shares Outstanding 14.86M
Market Cap 865.27M
EPS 2.20
P/E Ratio 20.36
Div & Yield N.A. (N.A)

Latest News

Eagle Pharmaceuticals Announces Clinical Development Plan Of Innovative Product Intended To Deliver Maximum Estrogen Receptor Inhibition In Patients With Estrogen Receptor (ER)-Positive Breast Cancer

Eagle Pharmaceuticals Announces Clinical Development Plan Of Innovative Product Intended To Deliver Maximum Estrogen Receptor Inhibition In Patients With Estrogen Receptor (ER)-Positive Breast Cancer

Eagle Pharmaceuticals, Inc. ("Eagle" or the "Company") (Nasdaq: EGRX) today announced a clinical development plan to support the submission of a New Drug Application (NDA) for the Company's innovative fulvestrant formulation.

Eagle Pharmaceuticals To Discuss Second Quarter 2019 Financial Results On August 8, 2019

Eagle Pharmaceuticals To Discuss Second Quarter 2019 Financial Results On August 8, 2019

Eagle Pharmaceuticals, Inc. ("Eagle" or the "Company") (Nasdaq: EGRX) today announced that the Company will release its 2019 second quarter financial results on Thursday, August 8, 2019, before the market opens.

Noteworthy Thursday Option Activity: EGRX, SWN, PLAY

Noteworthy Thursday Option Activity: EGRX, SWN, PLAY

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Eagle Pharmaceuticals, Inc. , where a total of 574 contracts have traded so far, representing approximately 57,400 underlying shares.

Eagle Pharmaceuticals Reaches Analyst Target Price

Eagle Pharmaceuticals Reaches Analyst Target Price

In recent trading, shares of Eagle Pharmaceuticals, Inc. have crossed above the average analyst 12-month target price of $51.00, changing hands for $51.76/share.

Eagle Pharmaceuticals, Inc. To Present At Jefferies 2019 Global Healthcare Conference

Eagle Pharmaceuticals, Inc. To Present At Jefferies 2019 Global Healthcare Conference

Eagle Pharmaceuticals, Inc. ("Eagle" or the "Company") (NASDAQ: EGRX) announced today that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will present at the Jefferies 2019 Global Healthcare Conference as follows:  ...

Eagle Pharmaceuticals, Inc. To Present At 2019 RBC Capital Markets Global Healthcare Conference

Eagle Pharmaceuticals, Inc. To Present At 2019 RBC Capital Markets Global Healthcare Conference

Eagle Pharmaceuticals, Inc. ("Eagle" or the "Company") (NASDAQ: EGRX) announced today that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will present at the 2019 RBC Capital Markets Global Healthcare Conference as...

Eagle Pharmaceuticals Breaks Above 200-Day Moving Average - Bullish For EGRX

Eagle Pharmaceuticals Breaks Above 200-Day Moving Average - Bullish For EGRX

In trading on Tuesday, shares of Eagle Pharmaceuticals, Inc. crossed above their 200 day moving average of $55.13, changing hands as high as $58.64 per share.

Eagle Pharmaceuticals, Inc. Reports First Quarter 2019 Results

Eagle Pharmaceuticals, Inc. Reports First Quarter 2019 Results

Eagle Pharmaceuticals, Inc. ("Eagle" or the "Company") (Nasdaq: EGRX) today announced its financial results for the three months ended March 31, 2019.

Eagle Pharmaceuticals Announces Positive Results Of A Study Conducted In Partnership With The U.S. Military To Evaluate Neuroprotective Effects Of RYANODEX For The Treatment Of Nerve Agent Exposure

Eagle Pharmaceuticals Announces Positive Results Of A Study Conducted In Partnership With The U.S. Military To Evaluate Neuroprotective Effects Of RYANODEX For The Treatment Of Nerve Agent Exposure

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ("Eagle" or the "Company") today announced positive results of its study to evaluate the neuroprotective effects of RYANODEX ® (dantrolene sodium) secondary to nerve agent (NA) exposure, conducted with the United...

Eagle Pharmaceuticals To Discuss First Quarter 2019 Financial Results On May 7, 2019

Eagle Pharmaceuticals To Discuss First Quarter 2019 Financial Results On May 7, 2019

Eagle Pharmaceuticals, Inc. ("Eagle" or the "Company") (Nasdaq: EGRX) today announced that the Company will release its 2019 first quarter financial results on Tuesday, May 7, 2019, before the market opens.

Don't Wait for the Green Light: Cramer's 'Mad Money' Recap (Wednesday, 4/24/19)

Don't Wait for the Green Light: Cramer's 'Mad Money' Recap (Wednesday, 4/24/19)

Jim Cramer says you cannot wait for the all-clear signal to buy because opportunities come long before that light turns green.

Halliburton, Micron Technology, AFLAC: 'Mad Money' Lightning Round

Halliburton, Micron Technology, AFLAC: 'Mad Money' Lightning Round

Jim Cramer takes a look at Halliburton, Micron Technology, AFLAC, Textron, Church & Dwight, Eagle Pharmaceuticals and more.

Eagle Pharmaceuticals Reaches Analyst Target Price

Eagle Pharmaceuticals Reaches Analyst Target Price

In recent trading, shares of Eagle Pharmaceuticals, Inc. have crossed above the average analyst 12-month target price of $51.00, changing hands for $52.06/share.

CMS Establishes Unique J-Code For BELRAPZO™ (Bendamustine 500mL Hydrochloride Injection)

CMS Establishes Unique J-Code For BELRAPZO™ (Bendamustine 500mL Hydrochloride Injection)

Eagle Pharmaceuticals, Inc. ("Eagle" or the "Company") (Nasdaq:EGRX) today announced that the Centers for Medicare & Medicaid Services (CMS) has established a unique, product-specific billing code, or J-code (J9036), for BELRAPZO ™ (bendamustine 500mL...

Eagle Pharmaceuticals, Inc. Expands Licensing Agreement For BENDEKA™ With Teva Pharmaceuticals International GmbH

Eagle Pharmaceuticals, Inc. Expands Licensing Agreement For BENDEKA™ With Teva Pharmaceuticals International GmbH

Eagle Pharmaceuticals, Inc. ("Eagle" or the "Company") (Nasdaq: EGRX) today announced that it has expanded its existing BENDEKA™ (bendamustine hydrochloride) licensing agreement with Teva Pharmaceuticals International GmbH ("Teva").

Rules of Biotech Investing Change, and So Must Biotech Investors

Rules of Biotech Investing Change, and So Must Biotech Investors

One big change over the last few years has been the struggle of small concerns to penetrate mass markets even with approved and superior drugs.

Eagle Pharmaceuticals, Inc. Reports Fourth Quarter And Full Year 2018 Results

Eagle Pharmaceuticals, Inc. Reports Fourth Quarter And Full Year 2018 Results

Eagle Pharmaceuticals, Inc. ("Eagle" or the "Company") (Nasdaq:EGRX) today announced its financial results for the three months and full year ended December 31, 2018.

Eagle Pharmaceuticals To Discuss Fourth Quarter And Full Year 2018 Financial Results On February 28, 2019

Eagle Pharmaceuticals To Discuss Fourth Quarter And Full Year 2018 Financial Results On February 28, 2019

Eagle Pharmaceuticals, Inc. ("Eagle" or the "Company") (Nasdaq: EGRX) today announced that the Company will release its 2018 fourth quarter and full year financial results on Thursday, February 28, 2019, before the market opens.

Eagle Pharmaceuticals, Inc. To Present At 37th Annual J.P. Morgan Healthcare Conference

Eagle Pharmaceuticals, Inc. To Present At 37th Annual J.P. Morgan Healthcare Conference

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ("Eagle" or the "Company") today announced that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will present at the 37th Annual J.

RSI Alert: Eagle Pharmaceuticals (EGRX) Now Oversold

RSI Alert: Eagle Pharmaceuticals (EGRX) Now Oversold

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Eagle Pharmaceuticals Announces Positive Results Of Pre-clinical Study Conducted To Evaluate Effects Of RYANODEX In Acute Radiation Syndrome (ARS)

Eagle Pharmaceuticals Announces Positive Results Of Pre-clinical Study Conducted To Evaluate Effects Of RYANODEX In Acute Radiation Syndrome (ARS)

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ("Eagle" or the "Company") today announced positive results of a proof-of-concept (POC) study in a Total-Body Radiation Animal Model.

Eagle Pharmaceuticals, Inc. To Present At 30th Annual Piper Jaffray Healthcare Conference

Eagle Pharmaceuticals, Inc. To Present At 30th Annual Piper Jaffray Healthcare Conference

Eagle Pharmaceuticals, Inc. (Nasdaq:EGRX) ("Eagle" or the "Company") today announced that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will present at the 30th Annual Piper Jaffray Healthcare Conference as follows:...

Eagle Pharmaceuticals Becomes Oversold (EGRX)

Eagle Pharmaceuticals Becomes Oversold (EGRX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Eagle Pharmaceuticals, Inc. To Present At 30th Annual Piper Jaffray Healthcare Conference

Eagle Pharmaceuticals, Inc. To Present At 30th Annual Piper Jaffray Healthcare Conference

Eagle Pharmaceuticals, Inc. (Nasdaq:EGRX) ("Eagle" or the "Company") today announced that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will present at the 30th Annual Piper Jaffray Healthcare Conference as follows:...

Eagle Pharmaceuticals, Inc. Reports Third Quarter 2018 Results

Eagle Pharmaceuticals, Inc. Reports Third Quarter 2018 Results

Eagle Pharmaceuticals, Inc. ("Eagle" or the "Company") (Nasdaq: EGRX) today announced its financial results for the three and nine months ended September 30, 2018.

Interesting EGRX Put And Call Options For November 16th

Interesting EGRX Put And Call Options For November 16th

Investors in Eagle Pharmaceuticals, Inc. saw new options begin trading this week, for the November 16th expiration.

Eagle Pharmaceuticals Is Now Oversold (EGRX)

Eagle Pharmaceuticals Is Now Oversold (EGRX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Eagle Pharmaceuticals Commences $50 Million Accelerated Share Repurchase As Part Of New $150 Million Share Repurchase Authorization

Eagle Pharmaceuticals Commences $50 Million Accelerated Share Repurchase As Part Of New $150 Million Share Repurchase Authorization

Eagle Pharmaceuticals, Inc. (Nasdaq:EGRX) ("Eagle" or the "Company") today provided preliminary financial results and announced that its Board of Directors has approved a new stock repurchase program providing for the repurchase of up to an aggregate of...

TheStreet Quant Rating: C+ (Hold)